Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Aashka Hospitals has entered into a non-binding agreement for its proposed tie-up with Vaidehi—Backbone hospital, Rajkot
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
PPH is associated with almost 20 per cent of maternal mortality in India
Subscribe To Our Newsletter & Stay Updated
